Skin health and disease最新文献

{"title":"Locally advanced basal cell carcinoma treated with sonidegib: <i>in vivo</i> monitoring with line-field confocal optical coherence tomography.","authors":"Simone Cappilli, Maria Mannino, Gerardo Palmisano, Enrico Bocchino, Alfredo Piccerillo, Andrea Paradisi, Alessandro Di Stefani, Ketty Peris","doi":"10.1093/skinhd/vzae025","DOIUrl":"10.1093/skinhd/vzae025","url":null,"abstract":"<p><strong>Background: </strong>Hedgehog pathway inhibitors, including sonidegib and vismodegib, represent the treatment strategy for 'difficult-to-treat' basal cell carcinoma (BCC), encompassing, among others, locally advanced (laBCC) and metastatic BCC. Assessment of therapy response is challenging due to the presence of telangiectasia and scar tissue at the area of the BCC lesion. Line-field confocal optical coherence tomography (LC-OCT) is a new noninvasive imaging technique that provides high-resolution visualization of skin structures.</p><p><strong>Objectives: </strong>To investigate the value of LC-OCT for the assessment of laBCC response to sonidegib therapy.</p><p><strong>Methods: </strong>We retrospectively included patients with laBCC treated with sonidegib in the period from May 2020 to May 2023. Patients with laBCC underwent LC-OCT at baseline before starting sonidegib, and after sonidegib discontinuation when clinical complete response (CR) was reached. A subset of patients underwent LC-OCT assessment during sonidegib therapy to assess tumour persistence.</p><p><strong>Results: </strong>Twenty laBCCs in 20 patients [4 women, 16 men; mean (SD) age 76 (18) years] treated with oral sonidegib 200 mg daily were included in the study. Ten patients obtained an apparent clinical CR; LC-OCT imaging confirmed CR in 7/10 patients (70%), while in the remaining patients (3/10, 30%) LC-OCT revealed findings indicative of BCC non-CR. Ten patients were continuing sonidegib treatment: in this group LC-OCT revealed findings suggestive of BCC persistence in all 10 patients (100%).</p><p><strong>Conclusions: </strong>In this study we provide preliminary results of the beneficial use of LC-OCT in the management of patients with laBCC treated with sonidegib therapy.</p>","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"5 1","pages":"37-40"},"PeriodicalIF":0.0,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11924395/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143694720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>In vitro</i> and <i>in vivo</i> efficacy of the Active Oligo Skin complex™, a new active ingredient processed from seawater, on multiple parameters of atopic skin.","authors":"Nicolas Lebonvallet, Chloé Catovic, Marc Feuilloley, Raphael Leschiera, Alexia Reux, Matthieu Talagas, Ianis Cousin, Laurent Misery, Emilie Simon, Sylvie Chopin, Johan Gardères","doi":"10.1093/skinhd/vzae029","DOIUrl":"10.1093/skinhd/vzae029","url":null,"abstract":"<p><strong>Background: </strong>Different symptoms are associated with atopic skin, including dryness, pruritus and pain, and affect patients' quality of life. The environment, microbiota, epidermis, immune and nerve cells are all implicated in the pathogenesis of atopic skin. <i>Staphylococcus aureus</i> is the focus of particular attention. Epidermis is implicated at multiple levels: inflammatory process, barrier, control of moisture and water loss. Sensory neurons that participate in cutaneous neurogenic inflammation and pruritus are seen as a potential new target. Specific management strategies and new treatments for adults and children are needed to help in more refractory cases. As a baseline of management, guidelines recommend a treatment to moisturize the skin and maintain the skin barrier function, such as an emollient.</p><p><strong>Objectives: </strong>To evaluate a new product <i>in vitro</i> and <i>in vivo</i> in order to validate the potential of its use in people with atopic skin or dry skin.</p><p><strong>Methods: </strong>A specific mineral composition, Active Oligo Skin complex™, from seawater was developed and included in a balm. The effects of a solution and balm containing the complex were evaluated <i>in vitro</i> on the growth and biofilm formation of <i>Staphylococcus aureus</i> and <i>Staphylococcus epidermidis</i> in different skin models, and <i>in vivo</i> in adult and young volunteers.</p><p><strong>Results: </strong><i>In vitro</i>, the complex modulated bacterial biofilm formation and growth, decreased cytokine [interleukin (IL)-1, IL-6, IL-4] and neuropeptide (substance P) release, and increased the expression of CL1 and CL4. On volunteers with dry skin, the complex had a moisturizing effect after 1 h of application. Dryness and roughness were also reduced in young participants with atopic skin. The balm decreased erythema and pruritus after 21 days of topical application on 60 young participants. On 22 adult participants, stinging score was decreased after -application.</p><p><strong>Conclusions: </strong>The Active Oligo Skin complex™ appears to display potent antipruritic and anti-inflammatory activities, both <i>in vitro</i> and <i>in vivo</i>.</p>","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"5 1","pages":"22-30"},"PeriodicalIF":0.0,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11924379/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143694160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Amitriptyline for the prevention of post herpetic neuralgia: study protocol for the ATHENA study.","authors":"Sian Wells, Stephanie J MacNeill, Yumeng Liu, Anna Gilbertson, Hazel Everitt, Oliver van Hecke, Jonathan Banks, Sophie Rees, Rebecca Kandiyali, Kirsty Garfield, Lorelei Hunt, Ioana Fodor, Vikki Wylde, Robert Johnson, Alastair D Hay, Anthony E Pickering, Matthew J Ridd","doi":"10.1093/skinhd/vzaf002","DOIUrl":"10.1093/skinhd/vzaf002","url":null,"abstract":"<p><strong>Background: </strong>Post herpetic neuralgia (PHN) is the most common complication of herpes zoster, also known as shingles. Amitriptyline has been postulated to prevent PHN. The objective is to determine whether prophylactic low-dose amitriptyline prevents PHN in patients newly diagnosed with shingles.</p><p><strong>Methods: </strong>This is a multicentre, individually randomized, pragmatic, placebo-controlled superiority trial with health economic analysis and nested qualitative study. Patients with new-onset shingles are screened by treating clinicians in participating general practitioner surgeries. Key eligibility criteria are age ≥50 years, ≤6 days since rash onset and not already taking (and no contraindication to) amitriptyline. Participants are randomized 1:1 to amitriptyline 10 mg or matched placebo tablets (dose escalated as tolerated to a maximum of three tablets daily for 70 days). Resource-use data (including health, social and informal care, personal expenses and usual activities) are collected from electronic medical records and participant questionnaires. A sample of recruitment conversations are audio-recorded and interviews conducted with recruiters and patients, including those who decline to participate or who withdraw from the trial.</p><p><strong>Discussion: </strong>The primary outcome is the presence of PHN (≥3/10 worst pain on Zoster Brief Pain Inventory) at 90 days after rash onset. Primary health economic analyses will present cost per case of PHN prevented and cost per quality-adjusted life year. Qualitative data will be analysed to optimize trial delivery and to aid interpretation and implementation of the trial findings. This is the largest trial to date to evaluate the clinical/cost-effectiveness and acceptability of prophylactic low-dose amitriptyline for the prevention of PHN.</p><p><strong>Protocol registration: </strong>EudraCT 2021-001101-78 and ISRCTN14490832.</p>","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"5 1","pages":"1-8"},"PeriodicalIF":0.0,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11924392/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143694540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Toxic epidermal necrolysis induced by axitinib in a patient with advanced lung adenocarcinoma.","authors":"Na Wang, Dongkai Li, Huaiwu He, Yun Long, Dawei Liu","doi":"10.1093/skinhd/vzae028","DOIUrl":"10.1093/skinhd/vzae028","url":null,"abstract":"<p><p>Patients taking oral EGFR inhibitors should be alert to the risk of TEN if they suddenly develop widespread rash.</p>","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"5 1","pages":"86-87"},"PeriodicalIF":0.0,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11924358/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143694736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unravelling the challenges of mycetoma: a case series highlighting diagnostic dilemmas and therapeutic triumphs.","authors":"Mahesh Mathur, Neha Thakur, Sunil Jaiswal, Sandhya Regmi, Supriya Paudel","doi":"10.1093/skinhd/vzae017","DOIUrl":"10.1093/skinhd/vzae017","url":null,"abstract":"<p><p>Mycetoma is a chronic suppurative granulomatous infection of the deep dermis and subcutaneous tissue prevalent in tropical and subtropical regions and is caused by filamentous aerobic bacteria (actinomycetoma) or true fungi (eumycetoma), representing 60% and 40% of cases worldwide, respectively. The causative organism enters into the subcutaneous tissue, usually of the foot, from contaminated soil or vegetative material through inoculation from a thorn prick, or repeated trauma. It commonly affects men, farmers and field workers. Differentiating eumycetoma from actinomycetoma can be challenging but is required before starting prolonged treatment. One of our patients presented with lesions on the thigh and in a sporotrichoid pattern that is atypical, while the other two patients were treated with antifungal medication for eumycetoma for years without proper investigation and improvement. Early diagnosis of actinomycetoma is mandatory to prevent tissue destruction, bone invasion and ultimate loss of function by proper investigative workup, histopathology and direct microscopy of discharge. We here report three cases of actinomycetoma with clinical and microbiology profiles treated successfully with tablets of trimethoprim-sulfamethoxazoleand amoxicillin-clavulanic acid along with folic acid as proposed by the Cochrane systemic review protocol 2018.</p>","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"5 1","pages":"61-65"},"PeriodicalIF":0.0,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11924367/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143694672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: The Development and Validation of a Decision Aid to Enhance Shared Decision-Making for the Management of Actinic Keratosis.","authors":"","doi":"10.1093/skinhd/vzaf003","DOIUrl":"https://doi.org/10.1093/skinhd/vzaf003","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1002/ski2.388.].</p>","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"5 1","pages":"93"},"PeriodicalIF":0.0,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11924355/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143694544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune checkpoint inhibitor-associated linear IgA bullous dermatosis with recalcitrant ocular involvement: a rare presentation.","authors":"Lina Saeed, Anna-Marie Hosking, Sergei A Grando","doi":"10.1093/skinhd/vzae008","DOIUrl":"10.1093/skinhd/vzae008","url":null,"abstract":"<p><p>Programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) receptor inhibitors have become imperative in the treatment of advanced solid organ malignancies such as metastatic melanoma. With this disinhibition of certain immune responses to induce an antitumour response, numerous adverse events have been reported, many of which affect the skin. While rare, PD-1/PD-L1 inhibitor-associated severe cutaneous adverse reactions (SCARs) can cause significant morbidity and/or mortality. New SCARs are reported with increasing frequency as immune checkpoint inhibitors become more widely used. Here, we present a rare case of recalcitrant ocular linear IgA bullous dermatosis associated with a PD-1 inhibitor. Awareness of this entity will allow more rapid recognition and initiation of appropriate management and treatment, which would reduce the morbidity and/or mortality associated with these serious adverse reactions.</p>","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"5 1","pages":"53-55"},"PeriodicalIF":0.0,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11924360/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143694717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Skin of colour dermatology education in US primary care residency programmes: a nationwide cross-sectional survey of programme directors.","authors":"Lauren C LaMonica, Thomas Hester, Reinie Thomas, Frank Wang","doi":"10.1093/skinhd/vzae001","DOIUrl":"10.1093/skinhd/vzae001","url":null,"abstract":"<p><strong>Background: </strong>Physicians-in-training report inadequate education in skin of colour (SOC) dermatology during residency. Although dermatology programmes have made progress in teaching SOC dermatology, the status of SOC dermatology education in primary care residency programmes remains unclear.</p><p><strong>Objectives: </strong>To characterize SOC didactic and clinical training opportunities available to primary care residents, laying the groundwork for future curriculum development of SOC dermatology.</p><p><strong>Methods: </strong>This cross-sectional study consisted of a nationwide 16-question survey disseminated by email between October 2022 and February 2023 to US primary care residency programmes identified using the Accreditation Council for Graduate Medical Education (ACGME) database.</p><p><strong>Results: </strong>Of responding programmes (<i>n</i> = 49/1224, 4.0%), 29/49 offered SOC didactic training, most often through integration of content within general dermatology lectures (<i>n</i> = 29/49, 59.2%) and board review sessions (<i>n</i> = 13/49, 26.5%). Over half of programmes (<i>n</i> = 35/49, 71.4%) offered SOC clinical training through rotation in a general dermatology clinic (<i>n</i> = 33/49, 67.3%) and skin-related chief concerns in primary care clinics (<i>n</i> = 29/49, 59.2%). Programmes with directors indicating that they planned to incorporate SOC education into future curricula (<i>n</i> = 20/49, 40.8%) were more likely to already have SOC didactic and clinical training opportunities (<i>P</i> = 0.01 and <i>P</i> = 0.02, respectively). Regarding future directions, programme directors were most interested in integrating SOC topics within dermatology lectures (<i>n</i> = 31/49, 63.3%); identifying an expert (<i>n</i> = 31/49, 63.3%) and allocating lecture time (<i>n</i> = 10/49, 20.4%) were the most frequently cited barriers.</p><p><strong>Conclusions: </strong>Some primary care programmes provide SOC dermatology didactic and clinical training opportunities, which are influenced by programme directors' willingness to incorporate such training into curricula, and present opportunities for dermatologists to educate primary care residents.</p>","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"5 1","pages":"9-13"},"PeriodicalIF":0.0,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11924359/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143694729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disseminated blastomycosis with cutaneous involvement in a young man in Ottawa, Canada.","authors":"Jaime N Turk, Laura D Chin, Stephanie L Petkiewicz, Steven J Glassman","doi":"10.1093/skinhd/vzae016","DOIUrl":"10.1093/skinhd/vzae016","url":null,"abstract":"","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"5 1","pages":"92"},"PeriodicalIF":0.0,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11924362/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143694545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rare finding of <i>Corynebacterium bovis</i> in a facial surgical wound.","authors":"Sach Thakker, Micah Belzberg, Elise Ng","doi":"10.1093/skinhd/vzae005","DOIUrl":"10.1093/skinhd/vzae005","url":null,"abstract":"","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"5 1","pages":"88-89"},"PeriodicalIF":0.0,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11924368/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143694723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}